Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 11:41 PM
Ignite Modification Date:
2025-12-25 @ 9:32 PM
NCT ID:
NCT03323151
Group ID:
EG001
Title:
Phase I: Ixazomib & Ibrutinib (Dose Level 2)
Description:
Ixazomib and Ibrutinib will be given by mouth until progression or unacceptable toxicity.
Ixazomib: Ixazomib 4 mg by mouth on days 1, 8 and 15 by mouth days 1-28 of a 28 day cycle.
Ibrutinib: Ibrutinib 560 mg by mouth days 1-28 of a 28 day cycle. Dose may be de-escalated (Ibrutinib 420 mg) or escalated (Ibrutinib 560 mg) dependent on dose-limiting toxicities.
Deaths Number Affected:
4
Deaths Number At Risk:
None
Serious Number Affected:
7
Serious Number At Risk:
9
Other Number Affected:
9
Other Number At Risk:
9
Study:
NCT03323151
Results Section:
NCT03323151
Adverse Events Module:
NCT03323151